
    
      The first 12-week period in this study was a dose-response study reported as Study M10-309
      (NCT00667576). Only subjects who completed 12 weeks in NCT00667576 were enrolled into this
      study (M10-312). Baseline in this study was the same as Baseline in NCT00667576. The duration
      of treatment in Study M10-312 was 40 weeks (for a total of 52 weeks, including NCT00667576).
    
  